Protein folding, molecule generation and AI-native drug pipelines. The lab bench is going computational.
181 articles
Hemispheric, a startup founded by a former Apple Face ID engineer, has emerged from stealth with $52M in funding. The company aims to use AI to analyze brain data as easily as a blood test.
The Next Web (TNW) · 65d ago
Dizal Pharmaceutical has transferred the global development and commercialization rights of its EGFR inhibitor Sunvozertinib back to its major shareholder, AstraZeneca, in a deal worth up to $1.5 billion.
虎嗅 · 66d ago
OpenAI researcher Miles Wang is reportedly in talks to launch a new AI-driven drug discovery startup. The venture is attracting significant interest, with Lightspeed Venture Partners in discussions to lead a funding round valuing the company at $2 billion.
TechCrunch AI · 66d ago
Major public funds are aggressively increasing their stakes in Hong Kong-listed innovative drug companies. This move is driven by low valuations and the potential for AI-driven research and development breakthroughs.
36氪 · 66d ago
Recent data shows a significant increase in cancer rates among individuals aged 15-39, largely attributed to lifestyle factors. However, medical breakthroughs like CAR-T cell therapy and ADC drugs are improving survival rates and treatment precision.
虎嗅 · 67d ago
The Chinese innovative drug licensing-out market is experiencing a structural shift, moving from single-asset deals to complex, long-term strategic partnerships involving AI-driven drug discovery and early-stage pipelines.
虎嗅 · 67d ago
Alina Su, a 25-year-old founder, shares her journey from Harvard Medical School dropout to CEO of Generation Lab, a longevity tech company that raised $15 million.
虎嗅 · 68d ago
The article analyzes the shifting power dynamics between Chinese biotech firms and global pharmaceutical giants. While global pharma once held all the leverage, the high efficiency and cost advantages of Chinese innovation have turned Chinese firms into essential partners in the global drug development pipeline.
虎嗅 · 68d ago
Researchers are leveraging the intersection of AI and quantum computing to accelerate the discovery of new peptides. This initiative aims to develop targeted drugs for rare diseases and underserved populations.
Wired AI · 69d ago
China's innovative drug sector shows strong growth, with 76 innovative drugs approved in 2025. Notably, the number of first-in-class domestic drugs has already exceeded the total for the previous year.
36氪 · 69d ago
Simcere Pharmaceutical has entered a global strategic partnership with Schrödinger to accelerate drug discovery and development. The collaboration leverages Schrödinger's computational platform to address unmet clinical needs through milestone-based development.
36氪 · 71d ago
Astellas Pharma is aggressively expanding its CLDN18.2-targeted oncology pipeline through acquisitions and partnerships to maintain its lead in gastric cancer treatment. The market is becoming increasingly competitive with ADC and bispecific antibody developments.
虎嗅 · 72d ago
China's brain-computer interface sector is experiencing a surge in venture funding and regulatory support. The industry is rapidly transitioning from academic research to clinical and commercial applications.
Pandaily · 73d ago
Celea Therapeutics secured $180M to test deuterated pirfenidone for pulmonary fibrosis, aiming to improve patient tolerance compared to the original drug.
虎嗅 · 73d ago
A 53-year-old brain-dead patient received a genetically edited pig liver and two kidneys, marking a milestone in multi-organ xenotransplantation. The study highlights both the functional success of the organs and the challenges of immune rejection.
虎嗅 · 74d ago
The pharmaceutical industry is entering a high-stakes competition to acquire and develop next-generation Antibody-Drug Conjugate (ADC) assets. This marks a critical moment for re-evaluating the value of these targeted therapies.
钛媒体 · 74d ago
Bexorg uses the BrainEx system to restore cellular activity in post-mortem human brains, creating a platform for testing neurological disease treatments. The company emphasizes that these brains lack consciousness and are used solely for metabolic and pharmacological research.
虎嗅 · 80d ago
Likang Life Sciences is building China's first AI-assisted personalized tumor vaccine production facility in Beijing. The center aims to address cancer treatment needs through advanced AI-driven manufacturing processes.
SCMP Technology · 82d ago
ByteDance and Anthropic are entering the AI-driven drug discovery market. The competition focuses on data and domain expertise rather than just algorithmic superiority.
钛媒体 · 85d ago
Everpure and Sanofi experts discuss how high-quality data integration accelerates drug discovery workflows. The conversation highlights the critical role of AI in streamlining pharmaceutical R&D processes.
Bloomberg Technology · 89d ago
The Chinese innovative drug sector is undergoing a major shift, marked by a series of high-value licensing deals. The industry is moving toward a model of systemic monetization and global integration.
钛媒体 · 89d ago
China is rapidly advancing its synthetic biology and biomanufacturing sector, utilizing AI-driven discovery to create 'cell factories.' These innovations range from artificial starch synthesis to advanced pharmaceutical development.
Pandaily · 91d ago
Midjourney CEO David Holz has unveiled 'The Midjourney Scanner,' a new hardware device that uses ultrasound sensors to create detailed internal body images. The company aims to provide image quality comparable to MRI scans for frequent health monitoring.
The Verge · 93d ago
Led by Xu Jinbo, Molecular Heart has raised over $100 million to build infrastructure for the global AI protein industry, aiming to lead the second paradigm revolution in AI biology.
量子位 · 94d ago
WuXi AppTec has been added to the US Department of Defense's 1260H list, citing indirect ties to the Chinese military. The company is suing to challenge this designation, which could impact its future in the US market under the Biosecure Act.
虎嗅 · 99d ago
Chinese oncologists are increasingly leading international clinical trials and presenting groundbreaking research at major conferences like ASCO, signaling a shift from followers to global leaders in oncology.
虎嗅 · 99d ago
The Allen Institute is launching a $400 million initiative to develop gene therapies for neurodegenerative diseases. This marks the organization's first strategic shift toward direct disease treatment.
GeekWire · 109d ago
Ruijian Medicine, a cell therapy platform, raised 210 million RMB in C1 funding led by Photo-Light Capital and Xingze Capital. The funds will accelerate their AI-driven chemical induction platform and clinical pipeline development.
36氪 · 110d ago
California Attorney General Rob Bonta has filed a lawsuit against 23andMe, alleging the company failed to protect sensitive genetic data and misled the public regarding the severity of a 2023 breach. The legal action highlights growing regulatory scrutiny over how biotech firms handle massive datasets used for AI-driven health research.
BBC Technology · 114d ago
Paris-based preventive-health startup Lucis has secured $20M in Series A funding just four months after its seed round. The platform combines blood biomarker testing with an AI-driven companion app to provide personalized health insights.
The Next Web (TNW) · 116d ago